Funder
Japan Society for the Promotion of Science
Subject
Cancer Research,Oncology,Hematology
Reference38 articles.
1. Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment;Ghiaur;Hematol. Oncol. Clin. N.,2017
2. FLT3 inhibitors: clinical potential in acute myeloid leukemia;Hospital;Onco Targets Ther.,2017
3. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial;Cortes;Lancet Oncol.,2018
4. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial;Cortes;Lancet Oncol.,2019
5. The growing landscape of FLT3 inhibition in AML;Smith;Hematol. Am. Soc. Hematol. Educ. Program,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A Review of FLT3 Kinase Inhibitors in AML;Journal of Clinical Medicine;2023-10-10